{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:30:54Z","timestamp":1787239854068,"version":"build-2736575974"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,7,22]],"date-time":"2023-07-22T00:00:00Z","timestamp":1689984000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,22]],"date-time":"2023-07-22T00:00:00Z","timestamp":1689984000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"DOI":"10.1007\/s12020-023-03450-3","type":"journal-article","created":{"date-parts":[[2023,7,22]],"date-time":"2023-07-22T03:01:26Z","timestamp":1689994886000},"page":"427-434","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Diagnosis and management of tumor-induced osteomalacia: a single center experience"],"prefix":"10.1007","volume":"82","author":[{"given":"Hulya","family":"Hacisahinogullari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakin","family":"Tekin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seher","family":"Tanrikulu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goktug","family":"Saribeyliler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gulsah Yenidunya","family":"Yalin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bilge","family":"Bilgic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emine Goknur","family":"Isik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet","family":"Salduz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuray","family":"Tuncer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nurdan","family":"Gul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayse Kubat","family":"Uzum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferihan","family":"Aral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Refik","family":"Tanakol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozlem Soyluk","family":"Selcukbiricik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,22]]},"reference":[{"issue":"3","key":"3450_CR1","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/ncpneph0124","volume":"2","author":"J Amanzadeh","year":"2006","unstructured":"J. Amanzadeh, R.F. Reilly Jr, Hypophosphatemia: an evidence-based approach to its clinical consequences and management. Nat. Clin. Pract. Nephrol. 2(3), 136\u2013148 (2006). https:\/\/doi.org\/10.1038\/ncpneph0124","journal-title":"Nat. Clin. Pract. Nephrol."},{"issue":"1","key":"3450_CR2","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1007\/s00223-020-00691-6","volume":"108","author":"P Florenzano","year":"2021","unstructured":"P. Florenzano, I.R. Hartley, M. Jimenez et al. Tumor-induced osteomalacia. Calcif. Tissue Int. 108(1), 128\u2013142 (2021). https:\/\/doi.org\/10.1007\/s00223-020-00691-6","journal-title":"Calcif. Tissue Int."},{"issue":"2","key":"3450_CR3","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s11154-015-9318-z","volume":"16","author":"JE Blau","year":"2015","unstructured":"J.E. Blau, M.T. Collins, The PTH-Vitamin D-FGF23 axis. Rev. Endocr. Metab. Disord. 16(2), 165\u2013174 (2015). https:\/\/doi.org\/10.1007\/s11154-015-9318-z","journal-title":"Rev. Endocr. Metab. Disord."},{"issue":"1","key":"3450_CR4","first-page":"33","volume":"16","author":"RA McCance","year":"1947","unstructured":"R.A. McCance, Osteomalacia with Looser\u2019s nodes (Milkman\u2019s syndrome) due to a raised resistance to vitamin D acquired about the age of 15 years. Q. J. Med. 16(1), 33\u201346 (1947)","journal-title":"Q. J. Med."},{"key":"3450_CR5","first-page":"554","volume":"14","author":"A Prader","year":"1959","unstructured":"A. Prader, R. Illig, E. Uehlinger et al. Rickets following bone tumor. Helv. Paediatr. Acta 14, 554\u2013565 (1959)","journal-title":"Helv. Paediatr. Acta"},{"issue":"2","key":"3450_CR6","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1210\/jcem.86.2.7408","volume":"86","author":"KE White","year":"2001","unstructured":"K.E. White, K.B. Jonsson, G. Carn et al. The autosomal dominant hypophosphatemic rickets (ADHR) gene is a secreted polypeptide overexpressed by tumors that cause phosphate wasting. J. Clin. Endocrinol. Metab. 86(2), 497\u2013500 (2001). https:\/\/doi.org\/10.1210\/jcem.86.2.7408","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"3450_CR7","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.mce.2008.10.052","volume":"299","author":"H Kurosu","year":"2009","unstructured":"H. Kurosu, M. Kuro-o, The Klotho gene family as a regulator of endocrine fibroblast growth factors. Mol. Cell Endocrinol. 299(1), 72\u201378 (2009)","journal-title":"Mol. Cell Endocrinol."},{"key":"3450_CR8","doi-asserted-by":"publisher","first-page":"189","DOI":"10.3389\/fendo.2018.00189","volume":"9","author":"B Richter","year":"2018","unstructured":"B. Richter, C. Faul, FGF23 actions on target tissues-with and without Klotho. Front. Endocrinol. 9, 189 (2018). https:\/\/doi.org\/10.3389\/fendo.2018.00189","journal-title":"Front. Endocrinol."},{"issue":"5","key":"3450_CR9","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1681\/ASN.2008070783","volume":"20","author":"EG Farrow","year":"2009","unstructured":"E.G. Farrow, S.I. Davis, L.J. Summers, K.E. White, Initial FGF23-mediated signaling occurs in the distal convoluted tubule. J. Am. Soc. Nephrol. 20(5), 955\u2013960 (2009)","journal-title":"J. Am. Soc. Nephrol."},{"issue":"2","key":"3450_CR10","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.bbrc.2003.12.102","volume":"314","author":"T Shimada","year":"2004","unstructured":"T. Shimada, I. Urakawa, Y. Yamazaki et al. FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa. Biochem. Biophys. Res. Commun. 314(2), 409\u2013414 (2004). https:\/\/doi.org\/10.1016\/j.bbrc.2003.12.102","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"11","key":"3450_CR11","doi-asserted-by":"publisher","first-page":"6500","DOI":"10.1073\/pnas.101545198","volume":"98","author":"T Shimada","year":"2001","unstructured":"T. Shimada, S. Mizutani, T. Muto et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc. Natl. Acad. Sci. USA 98(11), 6500\u20136505 (2001). https:\/\/doi.org\/10.1073\/pnas.101545198","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"3450_CR12","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1002\/jbmr.2606","volume":"31","author":"SK Murali","year":"2016","unstructured":"S.K. Murali, P. Roschger, U. Zeitz et al. FGF23 regulates bone mineralization in a 1,25(OH)2 D3 and Klotho-independent manner. J. Bone Miner. Res. 31(1), 129\u2013142 (2016). https:\/\/doi.org\/10.1002\/jbmr.2606","journal-title":"J. Bone Miner. Res."},{"issue":"4","key":"3450_CR13","doi-asserted-by":"publisher","first-page":"e1002427","DOI":"10.1371\/journal.pbio.1002427","volume":"14","author":"SK Murali","year":"2016","unstructured":"S.K. Murali, O. Andrukhova, E.L. Clinkenbeard et al. Excessive osteocytic Fgf23 secretion contributes to pyrophosphate accumulation and mineralization defect in Hyp mice. PLoS Biol. 14(4), e1002427 (2016). https:\/\/doi.org\/10.1371\/journal.pbio.1002427","journal-title":"PLoS Biol."},{"issue":"2","key":"3450_CR14","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1007\/s00223-011-9501-5","volume":"89","author":"V Shalhoub","year":"2011","unstructured":"V. Shalhoub, S.C. Ward, B. Sun et al. Fibroblast growth factor 23 (FGF23) and alpha-klotho stimulate osteoblastic MC3T3.E1 cell proliferation and inhibit mineralization. Calcif. Tissue Int. 89(2), 140\u2013150 (2011). https:\/\/doi.org\/10.1007\/s00223-011-9501-5","journal-title":"Calcif. Tissue Int."},{"issue":"7","key":"3450_CR15","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1507\/endocrj.EJ16-0587","volume":"64","author":"J Feng","year":"2017","unstructured":"J. Feng, Y. Jiang, O. Wang et al. The diagnostic dilemma of tumor induced osteomalacia: a retrospective analysis of 144 cases. Endocr. J. 64(7), 675\u2013683 (2017). https:\/\/doi.org\/10.1507\/endocrj.EJ16-0587","journal-title":"Endocr. J."},{"issue":"3","key":"3450_CR16","doi-asserted-by":"publisher","first-page":"R53","DOI":"10.1530\/ERC-11-0006","volume":"18","author":"WH Chong","year":"2011","unstructured":"W.H. Chong, A.A. Molinolo, C.C. Chen et al. Tumor-induced osteomalacia. Endocr. Relat. Cancer 18(3), R53\u2013R77 (2011). https:\/\/doi.org\/10.1530\/ERC-11-0006","journal-title":"Endocr. Relat. Cancer"},{"issue":"9","key":"3450_CR17","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1002\/jbmr.1642","volume":"27","author":"Y Jiang","year":"2012","unstructured":"Y. Jiang, W.B. Xia, X.P. Xing et al. Tumor-induced osteomalacia: an important cause of adult-onset hypophosphatemic osteomalacia in China: report of 39 cases and review of the literature. J. Bone Miner. Res. 27(9), 1967\u20131975 (2012). https:\/\/doi.org\/10.1002\/jbmr.1642","journal-title":"J. Bone Miner. Res."},{"issue":"1","key":"3450_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/00000478-200401000-00001","volume":"28","author":"AL Folpe","year":"2004","unstructured":"A.L. Folpe, J.C. Fanburg-Smith, S.D. Billings et al. Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am. J. Surg. Pathol. 28(1), 1\u201330 (2004). https:\/\/doi.org\/10.1097\/00000478-200401000-00001","journal-title":"Am. J. Surg. Pathol."},{"issue":"7929","key":"3450_CR19","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/s0140-6736(75)92736-1","volume":"2","author":"RJ Walton","year":"1975","unstructured":"R.J. Walton, O.L. Bijvoet, Nomogram for derivation of renal threshold phosphate concentration. Lancet 2(7929), 309\u2013310 (1975). https:\/\/doi.org\/10.1016\/s0140-6736(75)92736-1","journal-title":"Lancet"},{"key":"3450_CR20","doi-asserted-by":"publisher","first-page":"116064","DOI":"10.1016\/j.bone.2021.116064","volume":"152","author":"ML Brandi","year":"2021","unstructured":"M.L. Brandi, G.P.R. Clunie, P. Houillier, S.M. Jan de Beur, S. Minisola, R. Oheim, L. Seefried, Challenges in the management of tumor-induced osteomalacia (TIO). Bone 152, 116064 (2021)","journal-title":"Bone"},{"issue":"9308","key":"3450_CR21","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/s0140-6736(02)07846-7","volume":"359","author":"SM Jan de Beur","year":"2002","unstructured":"S.M. Jan de Beur, E.A. Streeten, A.C. Civelek et al. Localisation of mesenchymal tumours by somatostatin receptor imaging. Lancet 359(9308), 761\u2013763 (2002). https:\/\/doi.org\/10.1016\/s0140-6736(02)07846-7","journal-title":"Lancet"},{"issue":"11","key":"3450_CR22","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1097\/RLU.0b013e31818866bf","volume":"33","author":"M Duet","year":"2008","unstructured":"M. Duet, S. Kerkeni, R. Sfar et al. Clinical impact of somatostatin receptor scintigraphy in the management of tumor-induced osteomalacia. Clin. Nucl. Med. 33(11), 752\u2013756 (2008). https:\/\/doi.org\/10.1097\/RLU.0b013e31818866bf","journal-title":"Clin. Nucl. Med."},{"issue":"2","key":"3450_CR23","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1210\/jc.2012-3642","volume":"98","author":"RJ Clifton-Bligh","year":"2013","unstructured":"R.J. Clifton-Bligh, M.S. Hofman, E. Duncan et al. Improving diagnosis of tumor-induced osteomalacia with Gallium-68 DOTATATE PET\/CT. J. Clin. Endocrinol. Metab. 98(2), 687\u2013694 (2013). https:\/\/doi.org\/10.1210\/jc.2012-3642","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"10","key":"3450_CR24","doi-asserted-by":"publisher","first-page":"3575","DOI":"10.1210\/jc.2016-2052","volume":"101","author":"D El-Maouche","year":"2016","unstructured":"D. El-Maouche, S.M. Sadowski, G.Z. Papadakis et al. 68Ga-DOTATATE for tumor localization in tumor-induced osteomalacia. J. Clin. Endocrinol. Metab. 101(10), 3575\u20133581 (2016). https:\/\/doi.org\/10.1210\/jc.2016-2052","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"6","key":"3450_CR25","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1002\/jbmr.1881","volume":"28","author":"WH Chong","year":"2013","unstructured":"W.H. Chong, P. Andreopoulou, C.C. Chen et al. Tumor localization and biochemical response to cure in tumor-induced osteomalacia. J. Bone Miner. Res. 28(6), 1386\u20131398 (2013). https:\/\/doi.org\/10.1002\/jbmr.1881","journal-title":"J. Bone Miner. Res."},{"issue":"3","key":"3450_CR26","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1007\/s00774-016-0756-9","volume":"35","author":"WJ Yu","year":"2017","unstructured":"W.J. Yu, J.W. He, W.Z. Fu et al. Reports of 17 Chinese patients with tumor-induced osteomalacia. J. Bone Miner. Metab. 35(3), 298\u2013307 (2017). https:\/\/doi.org\/10.1007\/s00774-016-0756-9","journal-title":"J. Bone Miner. Metab."},{"issue":"3","key":"3450_CR27","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1002\/jbmr.3903","volume":"35","author":"X Li","year":"2020","unstructured":"X. Li, Y. Jiang, L. Huo et al. Nonremission and recurrent tumor-induced osteomalacia: a retrospective study. J. Bone Miner. Res. 35(3), 469\u2013477 (2020). https:\/\/doi.org\/10.1002\/jbmr.3903","journal-title":"J. Bone Miner. Res."},{"key":"3450_CR28","doi-asserted-by":"publisher","unstructured":"A.H. Hautmann, J. Schroeder, P. Wild et al. Tumor-induced osteomalacia: increased level of FGF-23 in a patient with a phosphaturic mesenchymal tumor at the tibia expressing periostin. Case Rep. Endocrinol. 729387 (2014). https:\/\/doi.org\/10.1155\/2014\/729387","DOI":"10.1155\/2014\/729387"},{"issue":"11","key":"3450_CR29","doi-asserted-by":"publisher","first-page":"4267","DOI":"10.1210\/jc.2013-2528","volume":"98","author":"VD Tarasova","year":"2013","unstructured":"V.D. Tarasova, A.G. Trepp-Carrasco, R. Thompson et al. Successful treatment of tumor-induced osteomalacia due to an intracranial tumor by fractionated stereotactic radiotherapy. J. Clin. Endocrinol. Metab. 98(11), 4267\u20134272 (2013). https:\/\/doi.org\/10.1210\/jc.2013-2528","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"4","key":"3450_CR30","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1053\/j.semdp.2019.07.002","volume":"36","author":"AL Folpe","year":"2019","unstructured":"A.L. Folpe, Phosphaturic mesenchymal tumors: a review and update. Semin. Diagn. Pathol. 36(4), 260\u2013268 (2019). https:\/\/doi.org\/10.1053\/j.semdp.2019.07.002","journal-title":"Semin. Diagn. Pathol."},{"issue":"2","key":"3450_CR31","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1002\/jbmr.4184","volume":"36","author":"Y Imanishi","year":"2021","unstructured":"Y. Imanishi, N. Ito, Y. Rhee et al. Interim analysis of a phase 2 open-label trial assessing burosumab efficacy and safety in patients with tumor-induced osteomalacia. J. Bone Miner. Res. 36(2), 262\u2013270 (2021). https:\/\/doi.org\/10.1002\/jbmr.4184","journal-title":"J. Bone Miner. Res."},{"issue":"4","key":"3450_CR32","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1002\/jbmr.4233","volume":"36","author":"SM Jan de Beur","year":"2021","unstructured":"S.M. Jan de Beur, P.D. Miller, T.J. Weber et al. Burosumab for the treatment of tumor-induced osteomalacia. J. Bone Miner. Res. 36(4), 627\u2013635 (2021). https:\/\/doi.org\/10.1002\/jbmr.4233","journal-title":"J. Bone Miner. Res."},{"issue":"7","key":"3450_CR33","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1210\/jc.2011-0385","volume":"96","author":"MF Holick","year":"2011","unstructured":"M.F. Holick, N.C. Binkley, H.A. Bischoff-Ferrari et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 96(7), 1911\u20131930 (2011). https:\/\/doi.org\/10.1210\/jc.2011-0385","journal-title":"J. Clin. Endocrinol. Metab."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-023-03450-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-023-03450-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-023-03450-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T03:09:04Z","timestamp":1696043344000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-023-03450-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,22]]},"references-count":33,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["3450"],"URL":"https:\/\/doi.org\/10.1007\/s12020-023-03450-3","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,22]]},"assertion":[{"value":"17 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Istanbul University, Istanbul Faculty of Medicine (Date: 23.02.2021\/No: 96235).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors affirm that human research participants provided informed consent for publication of the images in Fig.\n                      \n                      .","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}